Treatment options for non-motor symptoms in late-stage Parkinson's disease

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 4, 2008, Pages 523-535

  Coelho, Miguel ^a,b   Ferreira, Joaquim ^a,b   Rosa, Mário ^a,b   Sampaio, Cristina ^a,b  

^a INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Bone fractures; Dementia; Dysautonomia; Falls; Late stage Parkinson's disease; Pain; Psychosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; AMANTADINE; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; CISAPRIDE; CLOZAPINE; DOMPERIDONE; DONEPEZIL; DOPAMINE DERIVATIVE; ERGOCALCIFEROL; ETILEFRINE; FLUDOCORTISONE; LEVODOPA; MACROGOL; MIDODRINE; MINERALOCORTICOID; PLACEBO; QUETIAPINE; RISEDRONIC ACID; RIVASTIGMINE; SELEGILINE; TEGASEROD; THREO 3,4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE; BONE DENSITY CONSERVATION AGENT; CHOLINESTERASE INHIBITOR; GASTROINTESTINAL AGENT; NEUROLEPTIC AGENT; VASOCONSTRICTOR AGENT;

ABDOMINAL PAIN; AGITATION; ARTHROPATHY; BRONCHITIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEMENTIA; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSKINESIA; DYSPHAGIA; DYSTONIA; ESOPHAGITIS; FRACTURE; GAIT DISORDER; GASTROTOMY; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERSALIVATION; INTERSTITIAL NEPHRITIS; KINESIOTHERAPY; LEUKOPENIA; LOW DRUG DOSE; MUSCULOSKELETAL PAIN; MYOCARDITIS; NAUSEA; NECK PAIN; NEUROPATHIC PAIN; OCCUPATIONAL THERAPY; ORTHOPEDIC SURGERY; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PARKINSON DISEASE; PARKINSONISM; PHYSIOTHERAPY; PNEUMONIA; PSYCHOSIS; RADICULAR PAIN; REVIEW; SEDATION; SIDE EFFECT; SKELETON MALFORMATION; STOMACH PARESIS; SYSTOLIC HYPERTENSION; TREMOR; URINARY TRACT DISEASE; VENOUS THROMBOEMBOLISM; VOMITING; XEROSTOMIA; BONE DISEASE; DAILY LIFE ACTIVITY; DISEASE COURSE; EVIDENCE BASED MEDICINE; FALLING; GASTROINTESTINAL DISEASE; MICTURITION DISORDER; PAIN; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; TREATMENT OUTCOME;

ACCIDENTAL FALLS; ACTIVITIES OF DAILY LIVING; ANTIPSYCHOTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CHOLINESTERASE INHIBITORS; DEMENTIA; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; FRACTURES, BONE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; HYPOTENSION, ORTHOSTATIC; JOINT DISEASES; OCCUPATIONAL THERAPY; PAIN; PARKINSON DISEASE; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; TREATMENT OUTCOME; URINATION DISORDERS; VASOCONSTRICTOR AGENTS;

EID: 40649125791     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.4.523     Document Type: Review

References (98)

1. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006;5:75-86
2. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45
3. Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology 2000;55:S2-6
4. Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-16
5. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-9
6. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42
7. Goetz CG, Poewe W, Rascal O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-8
8. Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord 2005;20(Suppl 11):S23-9
9. Clarke CE. Mortality from Parkinson's disease in England and Wales 1921-89. J Neurol Neurosurg Psychiatry 1993;56:690-3
10. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol 1998;44:S1-9
11. Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:1941-50
12. Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21:677-92
13. Fabbrini G, Brotchie JM, Grandas F, et al. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-89
14. Moro E, Lang AE. Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Rev Neurother 2006;6:1695-705
15. Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-64
16. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002
17. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18
18. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21:456-61
19. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-9
20. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-12
21. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8
22. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating Parkinson's disease patients. Neurology 2000;55:789-94
23. Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000;15:1230-7
24. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000;15:301-4
25. Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007;109:188-91
26. Bilal L, Tsai C, Gasper JJ, Ndlela JC. Parkinsonism with intramuscular ziprasidone. Am J Psychiatry 2005;162:2392-3
27. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005;28:111-4
28. Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21:2078-81
29. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004;27:4-5
30. Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006;21:1538-9
31. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-63
32. Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-95
33. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57
34. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5
35. Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust NZ J Psychiatry 2004;38:915-22
36. Au AF, Luthra V, Stern R. Clozapine-induced acute interstitial nephritis. Am J Psychiatry 2004;161:1501
37. Elias TJ, Bannister KM, Clarkson AR, et al. Clozapine-induced acute interstitial nephritis. Lancet 1999;354:1180-1
38. Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000;355:1155-6
39. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-63
40. Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-8
41. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004;19:871-84
42. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-98
43. Deane KH, Jones D, Playford ED, et al. Physiotherapy for patients with Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev 2001:CD002817
44. Suchowersky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-82
45. Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007;78:134-40
46. Protas EJ, Mitchell K, Williams A, et al. Gait and step training to reduce falls in Parkinson's disease. NeuroRehabilitation 2005;20:183-90
47. Deane KH, Ellis-Hill C, Playford ED, et al. Occupational therapy for patients with Parkinson's disease. Cochrane Database Syst Rev 2001:CD002813
48. 2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord 2006;21:924-9
49. Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007;68:911-5
50. 3 in elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 66:64-8
51. Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006;21:1856-63
52. Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007;30:201-5
53. Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ 2005;331:1453-6
54. Tinazzi M, Del Vesco C, Fincati E, et al. Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:822-35
55. Drake DF, Harkins S, Qutubuddin A. Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation. NeuroRehabilitation 2005;20:335-41
56. Vaddadi G, Lambert E, Corcoran SJ, Esler MD. Postural syncope: mechanisms and management. Med J Aust 2007;187:299-304
57. Stocchi F. Gastrointestinal, urological. and sleep problems in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia: Butterworth Heinemann; 2005 p. 251-75
58. Robbins JA, Logemann JA, Kirshner HS. Swallowing and speech production in Parkinson's disease. Ann Neurol 1986;19:283-7
59. Deane KH, Ellis-Hill C, Jones D, et al. Systematic review of paramedical therapies for Parkinson's disease. Mov Disord 2002;17:984-91
60. Deane KH, Whurr R, Clarke CE, et al. Non-pharmacological therapies for dysphagia in Parkinson's disease. Cochrane Database Syst Rev 2001:CD002816
61. Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006;21:704-7
62. Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-81
63. Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-7
64. Bhatia KP, Munchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry 1999;67:697
65. Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord 2001;7:329-32
66. Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93-6
67. Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004;62:37-40
68. Thomsen TR, Galpern WR, Asante A, et al. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007;22:2268-73
69. Morgan JC, Sethi KD. Tegaserod in constipation associated with Parkinson disease. Clin Neuropharmacol 2007;30:52-4
70. Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007;22:1239-44
71. Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-45
72. Stocchi F. Depression, psychosis, and cognitive dysfunction in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia Butterworth Heinemann; 2005 p. 237-50
73. Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol 2005;4:423-31
74. Cooper IS. Neurosurgical treatment of the dyskinesias. Clin Neurosurg 1977;24:367-90
75. Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005;65:355-9
76. Kwak YT, Han IW, Baik J, Koo MS. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet 2000;355:2222
77. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, et al. Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 2007;78:1140-2
78. Goetz CG, Tanner CM, Levy M, et al. Pain in Parkinson's disease. Mov Disord 1986;1:45-9
79. Carette S, Moffet H, Tardif J, et al. Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. Arthritis Rheum 2003;48:829-38
80. Van Der Windt DA, Koes BW, Deville W, et al. Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial. BMJ 1998;317:1292-6
81. Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006;13:930-6
82. Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope - update 2004. Europace 2004;6:467-537
83. Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-9
84. Schroeder C, Bush VE, Norcliffe LJ, et al. Water drinking acutely improves orthostatic tolerance in healthy subjects. Circulation 2002;106:2806-11
85. Jordan J, Shannon JR, Grogan E, et al. A potent pressor response elicited by drinking water. Lancet 1999;353:723
86. Naschitz JE, Slobodin G, Elias N, Rosner I. The patient with supine hypertension and orthostatic hypotension: a clinical dilemma. Poatgrad Med J 2006;82:246-53
87. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-76
88. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-8
89. Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989;39:1309-14
90. Calne DB, Shaw DG, Spiers AS, Stern GM. Swallowing in parkinsonism. Br J Radiol 1970;43:456-7
91. Bramble MG, Cunliffe J, Dellipiani AW. Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson's disease. J Neurol Neurosurg Psychiatry 1978;41:709-12
92. Kempster PA, Lees AJ, Crichton P, et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Mov Disord 1989;4:47-52
93. Berkowitz DM, McCallum RW. Interaction of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980;27:414-20
94. Leon AS, Spiegel HE. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 1972;12:263-7
95. Abrams WB, Coutinho CB, Leon AS, Spiegel HE. Absorption and metabolism of levodopa. JAMA 1971;218:1912-4
96. Astarloa R, Mena MA, Sanchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992;15:375-80
97. Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989;46:1061-4
98. Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451-3